Determination of Genetic Relatedness of Linezolid-Resistant VRE Surveillance Cultures
Information source: University of Pittsburgh
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Isolate; Linezolid
Phase: N/A
Status: Recruiting
Sponsored by: University of Pittsburgh Official(s) and/or principal investigator(s):
Brian Potoski, Pharm D, Principal Investigator, Affiliation: University of Pittsburgh
Overall contact:
Brian Potoski, Pharm D, Phone: 412-648-6487, Email: potoskiba@upmc.edu
Summary
The study will help in identifying the best empiric antibiotic option for Linezolid
resistant VRE infections. This research is important because it allows the determination of
resistance rates to antibiotics that may not be frequently tested to by the clinical
microbiology laboratory at UPMC-Presbyterian. It also will provide antibiotic minimum
inhibitory concentrations (MICs) for these pathogens which may help in identifying the best
empiric antibiotic option for Linezolid resistant VRE infections.
Clinical Details
Official title: Determination of Genetic Relatedness of Linezolid-Resistant VRE Surveillance Cultures
Study design: Cohort, Retrospective
Detailed description:
After 20 linezolid-resistant VRE isolates are identified, genetic relatedness will be
determined using a method known as Pulse-field gel electrophoresis (PFGE). No patient
related data will accompany these isolates, nor will any related identifiers. These
isolates will be tested using standardized susceptibility methods. We will then grow each
isolate and test via approved laboratory standards (E-test, AB Biodisk, Stockholm, Sweden)
to the drug linezolid. Those determined to be resistant using this approved methodology will
be saved until 20 isolates are identified. For resistant isolates found, analytical and
molecular techniques will be performed to determine the mechanisms of resistance and whether
resistant isolates are coming from a single source/being transmitted from person to person.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Dr. Harrison's laboratory collected the rectal surveillance isolates for infection
control purposes. The isolates will be from January 1, 2006 to December 31, 2006.
Locations and Contacts
Brian Potoski, Pharm D, Phone: 412-648-6487, Email: potoskiba@upmc.edu
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, United States; Recruiting
Brian Potoski, Pharm D, Phone: 412-648-6487, Email: potoskiba@upmc.edu
Diana Lynn Pakstis, RN, BSN, Phone: 412-648-6553, Email: pakstisdl@dom.pitt.edu
Brian Potoski, Pharm D, Principal Investigator
Additional Information
Starting date: April 2007
Last updated: April 7, 2009
|
